Marcel Teichert

Essen, NW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

Journal: Haematologica
Published: April 15, 2026

Academic point-of-care anti-CD19 CAR T-cell therapy induces durable remission and transient paroxysmal nocturnal hemoglobinuria-type cell expansion in a patient with multi-refractory immune thrombocytopenia.

Academic point-of-care anti-CD19 CAR T-cell therapy induces durable remission and transient paroxysmal nocturnal hemoglobinuria-type cell expansion in a patient with multi-refractory immune thrombocytopenia.

Journal: Haematologica
Published: March 12, 2026

Prognostic role of FDG-PET in patients with relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies: a multicentric analysis.

Prognostic role of FDG-PET in patients with relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies: a multicentric analysis.

Journal: European journal of nuclear medicine and molecular imaging
Published: February 04, 2026

Feasibility and safety of rapid glofitamab ramp-up.

Feasibility and safety of rapid glofitamab ramp-up.

Journal: Leukemia
Published: January 20, 2026

Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

Journal: Blood cancer discovery
Published: December 03, 2025

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Journal: Haematologica
Published: October 17, 2025

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Journal: Haematologica
Published: October 17, 2025

Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland.

Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland.

Journal: Bone marrow transplantation
Published: July 27, 2025

Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysis.

Efficacy of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma and prior central nervous system manifestation: A multicenter real-world analysis.

Journal: HemaSphere
Published: January 30, 2025

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.

Journal: Blood cancer journal
Published: September 16, 2024

Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study.

Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study.

Journal: HemaSphere
Published: August 17, 2024

How to optimize the CAR-T Cell therapy process? A group concept mapping analysis of preconditions for a frictionless process from a German multistakeholder perspective.

How to optimize the CAR-T Cell therapy process? A group concept mapping analysis of preconditions for a frictionless process from a German multistakeholder perspective.

Journal: Frontiers in oncology
Published: July 18, 2024
Showing 1-12 of 14

Last Updated: 09/26/2026